Calcium-channel blockers - dihydropyridine (Formulary)

Refer to the Stable angina management guideline.

AMLODIPINE - (First line)

Important: Therapy notes

  • off-label indication for Raynaud’s phenomenon.

Important: Formulation and dosage details

Formulation:

Tablets 5mg, 10mg

Dosage:

Hypertension or angina: initially 5mg once daily, maximum 10mg once daily.

NIFEDIPINE

Important: Therapy notes

Long-acting formulations of nifedipine are recommended for angina or long-term management of hypertension but are off-label for use in Raynaud's phenomenon.

Modified-release preparations of nifedipine:

  • prescribe by brand name
  • select the most cost-effective brand when initiating therapy
  • hospitals will only stock some brands; contact Pharmacy to identify brands currently available
  • patients should continue on the same brand
  • consider once-daily preparations in new patients and when medicine is being changed.

Important: Formulation and dosage details

Formulation:

Modified release tablets 20mg, 30mg, 40mg, 60mg (once daily dosing)

Important: Formulation and dosage details

Formulation:

Modified release tablets 10mg, 20mg (twice daily dosing)

NIMODIPINE

Important: Therapy notes

MHRA advice: Drug-name confusion: reminder to be vigilant for potential errors (January 2018) (www.gov.uk)

Important: Formulation and dosage details

Formulation:

Tablets 30mg (hospital use only)

Dosage:

Prevention of ischaemic neurological defects following aneurysmal subarachnoid haemorrhage: by mouth, 60mg every 4 hours, starting within 4 days of event and continued for 21 days.

Important: Formulation and dosage details

Formulation:

Intravenous infusion 10mg/50mL (hospital use only)

Dosage:

Aneurysmal subarachnoid haemorrhage: refer to BNF and guidance

Editorial Information

Document Id: F054